| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | January 23, 2023 |
| Accession Number: | 0001171843-23-000361 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping more than 1% on Monday. The Dow traded down 0.90% to 32,625.78 while the NASDAQ fell 1.71% to 10,522.38. The S&P 500 also fell, dropping, 1.26% to 3,803.96. Also check this: Dow Records Losses For Second Straight Week But Investor Optimism Improves Leading and Lagging Sectors Energy shares rose by 0.4% on Monday. Meanwhile, top gainers in the sector included YPF Sociedad Anónima (NYSE:YPF), up 5%, and Mammoth Energy Services, Inc. (NASDAQ:TUSK), up 4%. In trading on Monday, communication services shares tumbled by 1.5%. Top Headline The NAHB housing market index declined two points to a reading of
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. Axcella Health Inc. (NASDAQ:AXLA) shares rose 153% to $0.4105. Axcella Health shares dipped 63% on Friday after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered its price target from $6 to $2. Camber Energy, Inc. (NYSE:CEI) shares climbed 103% to $0.1257 after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split. Qumu Corporation (NASDAQ:QUMU) gained 98.2% to $0.8722 after Enghouse Systems anno
Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) stock rose 232.5% to $212.11 during Monday's regular session. Trading volume for Madrigal Pharmaceuticals's stock is 6.6 million as of 12:30 EST. This is 2108.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.6 billion. Soleno Therapeutics (NASDAQ:SLNO) stock increased by 145.73% to $2.23. Soleno Therapeutics's stock is trading at a volume of 54.5 million shares as of 12:30 EST. This is 84775.2% of its average full-day volume over the last 100 days. The company's market cap stands at $18.1 million. Axcella Health (NASDAQ:AXLA) stock rose 109.74% to $0.34. As of 12:30 EST, this secu
SC 13G/A - Forward Pharma A/S (0001604924) (Subject)
SC 13G - Forward Pharma A/S (0001604924) (Subject)
SC 13G/A - Forward Pharma A/S (0001604924) (Subject)
EFFECT - Forward Pharma A/S (0001604924) (Filer)
POS AM - Forward Pharma A/S (0001604924) (Filer)
S-8 POS - Forward Pharma A/S (0001604924) (Filer)
COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("we" or "Forward"), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"),
COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("Forward" or the "Company"), today announced that the Enlarged Board of Appeal (the "EBA") of the European Patent Office (the "EPO") has denied Forward's petition for review (the "Petition") of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding ("Opposition Proceeding").The EBA's rejection of the Petition ends the Opposition Proceeding in favor of the opponents and represents an unsuccessful outcome of the Opposition Proceeding, resulting in no royalties being due to the Company from B
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("we," "Forward" or the "Company" and, together with its subsidiaries, the "Group"), today reported consolidated financial results for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was $1.9 million, or $0.02 per share, versus a net loss of $6.4 million, or $0.07 per share, for the year ended December 31, 2020. Our research, development, general and administrative costs increased from $3.4 million for the year ended December 31, 2020 to $3.9 million for the year ended December 31, 2021. Our net loss for the year ended December 31, 2021 was favorably impacted by a non